{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:33:07Z","timestamp":1792153987859,"version":"4.4.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA215134"],"award-info":[{"award-number":["R01-CA215134"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.bbmt.2018.03.027","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T13:26:46Z","timestamp":1522848406000},"page":"1546-1553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma"],"prefix":"10.1016","volume":"24","author":[{"given":"Rajshekhar","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty K.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-7927","authenticated-orcid":false,"given":"Shahrukh K.","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navneet S.","family":"Majhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.03.027_bib0010","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0015","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejca.2009.07.006","article-title":"Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989","volume":"46","author":"Schaapveld","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0020","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0025","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0030","series-title":"JAMA Users' Guide to Medical Literature","author":"Guyatt","year":"2015"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0035","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/asheducation-2015.1.501","article-title":"Patient-reported outcomes in clinical practice","volume":"2015","author":"Dobrozsi","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0045","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/leu.2013.185","article-title":"Review of health-related quality of life data in multiple myeloma patients treated with novel agents","volume":"27","author":"Sonneveld","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0050","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a Randomized Controlled Trial","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0060","doi-asserted-by":"crossref","first-page":"c2921","DOI":"10.1136\/bmj.c2921","article-title":"FDA guidance on patient reported outcomes","volume":"340","author":"Speight","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0065","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0070","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0075","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/sj.bmt.1700672","article-title":"Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale","volume":"19","author":"McQuellon","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0080","series-title":"A Guide to the Development of Certified Short Form Interpretation and Reporting Capabilities","author":"Maruish","year":"2009"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0090","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1385\/MO:18:1:65","article-title":"Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support","volume":"18","author":"Gulbrandsen","year":"2001","journal-title":"Med Oncol"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-0609.2004.00346.x","article-title":"Health related quality of life in patients with multiple myeloma undergoing a double transplantation","volume":"74","author":"Uyl-de Groot","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0105","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.057","article-title":"Quality of life assessment in multiple myeloma patients undergoing dose-reduced tandem autologous stem cell transplantation","volume":"3","author":"Khalafallah","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbmt.2008.09.023","article-title":"Changes in quality-of-life and psychosocial adjustment among multiple myeloma patients treated with high-dose melphalan and autologous stem cell transplantation","volume":"15","author":"Sherman","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0115","first-page":"1855","article-title":"Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients","volume":"66","author":"Etto","year":"2011","journal-title":"Clinics"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0120","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/bmt.2010.304","article-title":"A prospective evaluation of patients' health-related quality of life during auto-SCT: a 3-year follow-up","volume":"46","author":"Frodin","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1200\/JCO.2011.39.5137","article-title":"Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma","volume":"31","author":"Ludwig","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0130","first-page":"S67","article-title":"Study of quality of life in multiple myeloma patients after autologous stem cell transplantation","volume":"1","author":"Ashok","year":"2015","journal-title":"Indian J Hematol Blood Transfus"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0135","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3109\/10428194.2014.956313","article-title":"Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma","volume":"56","author":"Wang","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0140","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/cncr.23299","article-title":"Symptom burden after autologous stem cell transplantation for multiple myeloma","volume":"112","author":"Campagnaro","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0145","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/sj.bmt.1705664","article-title":"Symptom burden in patients undergoing autologous stem-cell transplantation","volume":"39","author":"Anderson","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0150","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood.V130.Suppl_1.681.681","article-title":"Symptom burden of busulfan and melphalan versus melphalan alone for multiple myeloma","volume":"130","author":"Williams","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0155","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.bbmt.2012.11.014","article-title":"Feasibility of frequent patient-reported outcome surveillance in patients undergoing hematopoietic cell transplantation","volume":"19","author":"Wood","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0160","first-page":"S139","article-title":"Influence of oral mucositis on the quality of life of patients treated with high-dose melphalan and autologous hematopoietic stem cell transplantation","volume":"21","author":"Toro","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0165","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood.V130.Suppl_1.680.680","article-title":"Reducing gastrointestinal toxicity associated with autologous transplantation for multiple myeloma without compromising its anti-myeloma effect","volume":"130","author":"Malek","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0170","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/bmt.2016.174","article-title":"Autologous stem cell transplant for multiple myeloma patients 70 years or older","volume":"51","author":"Muchtar","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0175","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.3324\/haematol.2016.150334","article-title":"Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study","volume":"101","author":"Garderet","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0180","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/bmt.2014.166","article-title":"Quality of life and outcomes in patients60 years of age after allogeneic hematopoietic cell transplantation","volume":"49","author":"Hamilton","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0185","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0190","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.bbmt.2012.11.065","article-title":"Cost effectiveness decision tree analysis of early versus late autologous stem cell transplantation (ASCT) in multiple myeloma (MM) in the United States (US)","volume":"1","author":"Hashmi","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"10.1016\/j.bbmt.2018.03.027_bib0195","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1182\/blood-2016-09-692947","article-title":"Next-generation multiple myeloma treatment: a pharmacoeconomic perspective","volume":"128","author":"Rajkumar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12882","article-title":"A systematic review of health-related quality of life in longitudinal studies of myeloma patients","volume":"99","author":"Nielsen","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0205","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","article-title":"Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life","volume":"46","author":"Boland","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0210","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/bmt.2016.113","article-title":"Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN","volume":"51","author":"Shaw","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0215","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.bbmt.2018.03.027_bib0220","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11136-017-1759-2","article-title":"Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma","volume":"27","author":"Shah","year":"2017","journal-title":"Qual Life Res"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0225","first-page":"657","article-title":"Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial","volume":"26","author":"Deng","year":"2018","journal-title":"Supportive Care Cancer"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0230","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.bbmt.2015.07.036","article-title":"Higher stem cell dose infusion after intensive chemotherapy does not improve symptom burden in older patients with multiple myeloma and amyloidosis","volume":"22","author":"Shah","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.03.027_bib0235","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood.V128.22.537.537","article-title":"Health-related quality of life of patients with newly diagnosed multiple myeloma receiving any or lenalidomide maintenance after autologous stem cell transplant in the connect MM disease registry","volume":"128","author":"Abonour","year":"2016","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118301617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118301617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:02:56Z","timestamp":1761058976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118301617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1083879118301617"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.03.027","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}